Investigation of the Cylex® ImmuKnow® Assay

Indiana University School of Medicine

Status: Completed

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Myeloproliferative Disorders; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Aplastic Anemia; Leukemia; Myelodysplastic Syndromes

Study type: Observational

Funder types: Other

Identifiers

NCT00569842

0710-11/ IUCRO-0207

Details and patient eligibility

About

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

Enrollment: 45 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:

1. Acute leukemia
2. Non-Hodgkin's Lymphoma
3. Chronic lymphocytic leukemia
4. Hodgkin's disease
5. Multiple myeloma
6. Myelodysplastic Syndromes
7. Myeloproliferative Disorders
8. Aplastic Anemia
9. Chronic myelogenous leukemia

Trial design

45 participants in 1 patient group

observational